X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DR. REDDYS LAB - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DR. REDDYS LAB CADILA HEALTHCARE/
DR. REDDYS LAB
 
P/E (TTM) x 32.1 29.7 108.1% View Chart
P/BV x 6.0 2.9 205.0% View Chart
Dividend Yield % 0.8 0.9 84.9%  

Financials

 CADILA HEALTHCARE   DR. REDDYS LAB
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
DR. REDDYS LAB
Mar-17
CADILA HEALTHCARE/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs4603,397 13.5%   
Low Rs3052,560 11.9%   
Sales per share (Unadj.) Rs92.1856.5 10.8%  
Earnings per share (Unadj.) Rs14.878.0 19.0%  
Cash flow per share (Unadj.) Rs18.5139.9 13.2%  
Dividends per share (Unadj.) Rs3.2020.00 16.0%  
Dividend yield (eoy) %0.80.7 124.6%  
Book value per share (Unadj.) Rs68.0739.8 9.2%  
Shares outstanding (eoy) m1,023.74165.74 617.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.23.5 119.4%   
Avg P/E ratio x25.838.2 67.6%  
P/CF ratio (eoy) x20.721.3 97.2%  
Price / Book Value ratio x5.64.0 139.8%  
Dividend payout %21.625.7 84.2%   
Avg Mkt Cap Rs m391,581493,632 79.3%   
No. of employees `00016.922.7 74.3%   
Total wages/salary Rs m15,00231,068 48.3%   
Avg. sales/employee Rs Th5,594.56,259.0 89.4%   
Avg. wages/employee Rs Th890.11,369.8 65.0%   
Avg. net profit/employee Rs Th899.9569.7 158.0%   
INCOME DATA
Net Sales Rs m94,295141,961 66.4%  
Other income Rs m1,2861,715 75.0%   
Total revenues Rs m95,581143,676 66.5%   
Gross profit Rs m19,03624,722 77.0%  
Depreciation Rs m3,75010,266 36.5%   
Interest Rs m450634 71.0%   
Profit before tax Rs m16,12215,537 103.8%   
Minority Interest Rs m3380-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2892,965 43.5%   
Profit after tax Rs m15,16812,921 117.4%  
Gross profit margin %20.217.4 115.9%  
Effective tax rate %8.019.1 41.9%   
Net profit margin %16.19.1 176.7%  
BALANCE SHEET DATA
Current assets Rs m60,22396,837 62.2%   
Current liabilities Rs m53,05884,199 63.0%   
Net working cap to sales %7.68.9 85.4%  
Current ratio x1.11.2 98.7%  
Inventory Days Days7073 95.2%  
Debtors Days Days8898 90.3%  
Net fixed assets Rs m72,984102,552 71.2%   
Share capital Rs m1,024829 123.5%   
"Free" reserves Rs m68,576121,792 56.3%   
Net worth Rs m69,600122,621 56.8%   
Long term debt Rs m24,6845,449 453.0%   
Total assets Rs m152,207218,165 69.8%  
Interest coverage x36.825.5 144.4%   
Debt to equity ratio x0.40 798.1%  
Sales to assets ratio x0.60.7 95.2%   
Return on assets %10.36.2 165.1%  
Return on equity %21.810.5 206.8%  
Return on capital %17.912.9 139.0%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m21,28081,670 26.1%   
Fx outflow Rs m10,87426,355 41.3%   
Net fx Rs m10,40655,315 18.8%   
CASH FLOW
From Operations Rs m13,49521,444 62.9%  
From Investments Rs m-29,103-18,404 158.1%  
From Financial Activity Rs m23,158-3,692 -627.2%  
Net Cashflow Rs m7,556-1,144 -660.5%  

Share Holding

Indian Promoters % 74.8 25.5 293.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.4 153.7%  
FIIs % 5.9 35.3 16.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 11.0 15.3 71.9%  
Shareholders   44,069 75,885 58.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  ELDER PHARMA  VENUS REMEDIES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Healthcare & Metal Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.17% while the Hang Seng is up 0.95%. The Nikkei 225 is trading up by 0.4%.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 23, 2018 09:47 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS